Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million.
周二，Esperion Therapeutics（纳斯达克股票代码：ESPR）公布的第一季度收入为1.374亿美元，同比增长467％，超过了市场预期的8451万美元。
The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05.
该公司公布的每股收益为0.34美元，较去年同期的每股亏损0.79美元（0.79美元）有所扭转，超过了市场预期的0.05美元。
U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growth within partner territories along with the settlement-related milestone payment.
美国净产品收入为2480万美元，同比增长约46％。协作收入为1.13亿美元，而去年同期为730万美元，这得益于对国际合作伙伴的平板电脑销售增加以及合作伙伴区域内的销售增长以及与和解相关的里程碑付款。
"We posted retail prescription equivalent growth of 43% year-over-year, generated our highest level of revenue yet, and ended the quarter with a cash balance that positions us to capitalize on our new label and deliver long-term value growth," said Sheldon Koenig, President and CEO.
总裁兼首席执行官谢尔登·科尼格表示：“我们公布的零售处方等价物同比增长了43％，创造了迄今为止最高的收入水平，并在本季度末实现了现金余额，使我们能够利用新标签并实现长期价值增长。”
In March, the FDA approved broad new label expansions for Esperion Therapeutics' NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in primary and secondary prevention patients.
3月，美国食品药品管理局根据CLEAR结果数据，批准了Esperion Therapeutics的NEXLETOL（本培多酸）片剂和NEXLIZET（本培多酸和依泽替米贝）片剂的广泛新标签扩展，其中包括降低初级和二级预防患者的心血管风险和扩大降低低密度脂蛋白的适应症。
During the quarter, the company initiated new commercial initiatives to increase patient awareness of NEXLETOL and NEXLIZET's expanded labels. Expanded sales force to 150 representatives in the U.S. and developed new promotional materials and tools to supplement salesforce efforts.
在本季度，该公司启动了新的商业举措，以提高患者对NEXLETOL和NEXLIZET扩展标签的认识。将销售队伍扩大到美国的150名代表，并开发了新的宣传材料和工具以补充销售队伍的工作。
The company initiated the technology transfer process for NILEMDO and NUSTENDI tablet manufacturing to Daiichi Sankyo Europe for its territories, which is expected to be completed in the second half of 2025.
该公司启动了向第一三共欧洲公司在其领土上生产NILEMDO和NUSTENDI平板电脑的技术转让程序，该过程预计将于2025年下半年完成。
Additionally, as part of the amended partnership, the company authorized Daiichi Sankyo Europe to proceed with commercialization of a triple formulation product comprising bempedoic acid, ezetimibe, and a statin, which, if approved, has the potential to extend the product's lifecycle in Europe.
此外，作为修订后的合作伙伴关系的一部分，该公司授权第一三共欧洲公司着手将一种包含本培多酸、依折替米贝和他汀类药物的三联配方产品的商业化，如果获得批准，有可能延长该产品在欧洲的生命周期。
Guidance: Esperion Therapeutics expects fiscal year 2024 operating expenses of $225 million-$245 million.
指导方针：Esperion Therapeutics预计，2024财年的运营支出为2.25亿至2.45亿美元。
Price Action: ESPR shares are up 5.20% at $2.23 at last check Tuesday.
价格走势：周二最后一次检查时，ESPR股价上涨5.20％，至2.23美元。
译文内容由第三方软件翻译。